ライフサイエンスコーパス: adoptive cell transfer

1 and regress multiple solid tumors following adoptive cell transfer.

2 ine delivery or optimal T cell expansion for adoptive cell transfer.

3 tive target for TCR-based gene therapy using adoptive cell transfer.

4 r tumor rejection or inhibit treatment after adoptive cell transfer.

5 e of circulating antitumor T cells following adoptive cell transfer.

6 N-gamma-/- mice, were used as recipients for adoptive cell transfer.

7 tive vaccines and strategies for therapeutic adoptive cell transfer.

8 lymphocytes from melanoma patients following adoptive cell transfer.

9 pulations were rejected within 18 days after adoptive cell transfer.

10 ns and reducing the therapeutic potential of adoptive cell transfers.

11 such as administration of the cytokine IL-2, adoptive cell transfer (ACT) and the recent success of b

12 Depletion of immune elements before adoptive cell transfer (ACT) can dramatically improve th

13 Adoptive cell transfer (ACT) is considered a promising m

14 The field of adoptive cell transfer (ACT) is currently comprised of c

15 umor microenvironment (TME), the efficacy of adoptive cell transfer (ACT) is much curtailed in treati

16 the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes

17 Adoptive cell transfer (ACT) of ex vivo-activated autolo

18 Adoptive cell transfer (ACT) of purified naive, stem cel

19 A key issue in advancing the use of adoptive cell transfer (ACT) of T cell receptor (TCR) en

20 Immunotherapy, particularly the adoptive cell transfer (ACT) of tumor-infiltrating lymph

21 Adoptive cell transfer (ACT) of tumor-reactive lymphocyt

22 Recently, adoptive cell transfer (ACT) of tumor-reactive T lymphoc

23 dy that describes a potential new target for adoptive cell transfer (ACT), in this case CD44 splice v

24 esponse is enhanced through a combination of adoptive cell transfer (ACT), specific vaccination and c

25 Adoptive cell transfer (ACT)-based immunotherapies can m

26 sentially as an adjuvant immunotherapy, with adoptive cell transfer (ACT).

27 f successful cancer immunotherapies, such as adoptive cell transfer and antibody-based immunotherapeu

28 Adoptive cell transfer and cell depletion studies reveal

29 its functional loss reduces the efficacy of adoptive cell transfer and checkpoint blockade immunothe

30 Before the adoptive cell transfer and DC vaccination, the tumor-bea

31 r, did not require total body irradiation or adoptive cell transfer and resulted in induction of anti

32 ls, with potential clinical implications for adoptive cell transfer and vaccine-based immunotherapies

33 Adoptive cell transfer and vascularized segmental pancre

34 ts for successful tumor rejection through an adoptive cell transfer approach reveals that the presenc

35 Furthermore, by using an adoptive cell transfer approach, reconstitution of B cel

36 ere dissected using bone marrow chimeras and adoptive cell transfer approaches to profile clonal expa

37 dity, which limits their clinical utility in adoptive cell transfer approaches.

38 eric antigen receptor (CAR) for T-cell-based adoptive cell transfer are among these developments that

39 Immunotherapies based on adoptive cell transfer are highly effective in the treat

40 Adoptive cell transfer can mediate durable complete regr

41 upport suggests that IL-12 could be added to adoptive cell transfer clinical strategies in cancer pat

42 Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, p

43 In vivo depletion and adoptive cell transfer experiments demonstrated that bot

44 Adoptive cell transfer experiments demonstrated that Sph

45 Adoptive cell transfer experiments establish an intrinsi

46 Furthermore, use of gene-deficient mice and adoptive cell transfer experiments revealed that ILC2s w

47 ent tumor models suppressed CTL responses in adoptive cell transfer experiments unless GM-CSF was pro

48 tumor-sensitized T cells is demonstrated by adoptive cell transfer experiments using purified spleen

49 in both mixed bone marrow-chimeric mice and adoptive cell transfer experiments.

50 protection using anti-CD8 mAb depletion and adoptive cell transfer experiments.

51 tyrosinase-specific TCR could be of value in adoptive cell transfer for melanoma.

52 the main challenge to the development of TIL adoptive cell transfer for metastatic GI cancers may not

53 -1/PD-L1 and CTLA-4 checkpoints blockade and adoptive cell transfer) have remarkably improved the res

54 ith porcine skin grafts and administered, by adoptive cell transfer, human cells stimulated in vitro

55 In the setting of adoptive cell transfer, IL-15-transduced lymphocytes may

56 corporating tumor-reactive CD4(+) T cells in adoptive cell transfer immunotherapies against ovarian c

57 ion of the lung and improves the efficacy of adoptive cell transfer immunotherapy.

58 ilic airways inflammation upon intratracheal adoptive cell transfer into congenic mice.

59 cell compartment in immunodeficient mice by adoptive cell transfer leads to a wasting syndrome and i

60 for administering high levels of IL-2 during adoptive cell transfer-mediated antitumor responses.

61 The adoptive cell transfer model described in this paper can

62 We have developed an adoptive cell transfer model in mice to study the abilit

63 re analyzed using cytokine reporter mice, an adoptive cell transfer model, and gene knockout mice.

64 the tolerized mice for testing in active and adoptive cell-transfer models of CS.

65 Adoptive cell transfer of ex vivo-generated immune-promo

66 Adoptive cell transfer of macrophages with immunosuppres

67 us immunotherapies under development such as adoptive cell transfer of TCR-engineered CD8(+) T cells,

68 Adoptive cell transfer of tumor-infiltrating lymphocytes

69 clonotypes that persisted in vivo following adoptive cell transfer possessed telomeres that were lon

70 We have developed an adoptive cell transfer protocol to further characterize

71 -engineered T cells are a novel approach for adoptive cell transfer, providing flexible platform for

72 In this study, we used an adoptive cell-transfer strategy to define the protective

73 Using adoptive cell transfer studies in mouse models of allerg

74 Adoptive cell transfer studies showed that RAG2(-/-) rec

75 Adoptive cell transfer, the infusion of large numbers of

76 Upon adoptive cell transfer, the T cells isolated from the me

77 e significant progress in the development of adoptive cell-transfer therapies (ACTs) using gene-engin

78 Adoptive cell transfer therapy has emerged as a powerful

79 sary for antitumor activity of Th17 cells in adoptive cell transfer therapy models.

80 Combined treatment of vemurafenib plus adoptive cell transfer therapy with lymphocytes genetica

81 hways (i.e. PD-1, CTLA-4, and IDO); and (iv) adoptive cell transfer therapy with T cells engineered t

82 e yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a

83 to enhance the effect of cancer vaccines or adoptive cell transfer therapy.

84 major implications for the design of current adoptive-cell transfer trials.

85 ession of CTLs that is often observed during adoptive cell transfer tumor immunotherapy and identify

86 Adoptive cell transfer utilizing tumour-targeting cytoto

87 mice missing different leukocyte subsets and adoptive cell transfers, we demonstrated the involvement

88 Finally, adoptive cell transfers were implemented to characterize

89 Finally, adoptive cell transfers were performed to characterize t

90 with agents that augment host immunity, and adoptive cell transfer will be discussed.